Literature DB >> 12565816

Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes.

Andrei L Gartel1, Ksenya Shchors.   

Abstract

Constitutive expression of the proto-oncogene c-myc results in oncogenic activation and contributes to progression of a wide range of human and animal tumors. Myc executes its multiple activities mostly through transcriptional regulation of the target genes. The special interest of this review is the mechanism of transcriptional repression of cell cycle inhibitors by Myc. Myc suppresses expression of cell cycle/growth arrest genes gas1, p15, p21, p27, and gadd34, -45, and -153. It appears that Myc represses growth arrest gene transcription by at least two distinct mechanisms. One mechanism is limited to the binding of Myc-Max heterodimers to the Inr element in their promoters and inhibition of Miz-1 or other transcriptional activators via the C-terminal domain of c-Myc. This mechanism requires DNA binding of the Myc-Max complex to Inr sequences. The other mechanism is dependent on c-Myc binding to the Sp1 transcription factor via the c-Myc central region and inhibition of Sp1 transcriptional activity. At this time it is not entirely clear which Sp1-containing promoters will be repressed by c-Myc and what other modes of c-Myc transcriptional repression may exist. The ability of c-Myc to repress transcription of growth arrest genes may contribute to its potential to promote proliferation and oncogenesis. Copyright 2003 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565816     DOI: 10.1016/s0014-4827(02)00020-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  81 in total

1.  In silico identification of transcriptional regulators associated with c-Myc.

Authors:  Ran Elkon; Karen I Zeller; Chaim Linhart; Chi V Dang; Ron Shamir; Yosef Shiloh
Journal:  Nucleic Acids Res       Date:  2004-09-23       Impact factor: 16.971

2.  Epigenetic reprogramming of Myc target genes.

Authors:  Stefano Amente; Luigi Lania; Barbara Majello
Journal:  Am J Cancer Res       Date:  2011-02-06       Impact factor: 6.166

3.  Overexpression of nuclear distribution protein (hNUDC) causes pro-apoptosis and differentiation in Dami megakaryocytes.

Authors:  Y Xiao; Y Zheng; P Tan; P Xu; Q Zhang
Journal:  Cell Prolif       Date:  2013-09-07       Impact factor: 6.831

4.  N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.

Authors:  Michael B Armstrong; Rajen J Mody; D Christian Ellis; Adam B Hill; David A Erichsen; Daniel S Wechsler
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

5.  Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Authors:  Yinfei Tan; Eleonora Sementino; Jonathan Chernoff; Joseph R Testa
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

6.  Propeller-type parallel-stranded G-quadruplexes in the human c-myc promoter.

Authors:  Anh Tuân Phan; Yasha S Modi; Dinshaw J Patel
Journal:  J Am Chem Soc       Date:  2004-07-21       Impact factor: 15.419

7.  HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.

Authors:  Minori Koshiji; Yukio Kageyama; Erin A Pete; Izumi Horikawa; J Carl Barrett; L Eric Huang
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.

Authors:  Junling Si; Xueyan Yu; Yingjie Zhang; James W DeWille
Journal:  Mol Cancer       Date:  2010-04-28       Impact factor: 27.401

10.  ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway.

Authors:  Zhe-Yu Hu; Jian Sun; Xiao-Feng Zhu; Dajun Yang; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.